By Product Type
By Research Area
|Refer to a mixture of immunoglobulin molecules that are secreted against a particular antigen.||Refer to a homogenous population of antibodies that are produced by a single clone of plasma B cells.|
|Produced by different clones of plasma B cells.||Produced by the same clone of plasma B cells.|
|Production does not require hybridoma cell lines.||Production requires hybridoma cell lines.|
|A heterogeneous antibody population.||A homogenous antibody population.|
|Interact with different epitopes on the same antigen.||Interact with a particular epitope on the antigen.|
Inexpensive and relatively quick to produce (+/- 3 months).
Higher overall antibody affinity against the antigen due to the recognition of multiple epitopes.
Have a high sensitivity for detecting low-quantity proteins.
High ability to capture the target protein (recommended as the capture antibody in a sandwich ELISA).
Antibody affinity results in quicker binding to the target antigen (recommended for assays that require quick capture of the protein; e.g., IP or ChIP).
Superior for use in detecting a native protein.
Easy to couple with antibody labels and rather unlikely to affect binding capability.
Batch-to-batch variability as produced in different animals at different times.
High chance of cross-reactivity due to a recognition of multiple epitopes (affinity purified antibodies display a minimum cross-reactivity).
Batch-to-batch reproducibility (high homogeneity).
Possibility to produce large quantities of identical antibody (an advantage for diagnostic manufacturing and therapeutic drug development).
High specificity to a single epitope reflected in low cross-reactivity.
More sensitive in assays requiring quantification of the protein levels.
Low background noise.
More expensive to produce. It is necessary to produce a pool of several monoclonal antibodies.
Requires significantly more time to produce and develop the hybridized clone (+/- 6 months).
More susceptible to binding changes when labeled.
Polyclonal antibodies are made using several different immune cells. They will have the affinity for the same antigen but different epitopes, while monoclonal antibodies are made using identical immune cells that are all clones of a specific parent cell (Figure 1).
For applications such as therapeutic drug development that require large volumes of identical antibody specific to a single epitope, monoclonal antibodies are a better solution. For general research applications, however, the advantages of polyclonal antibodies typically outweigh the few advantages that monoclonal antibodies provide. With affinity purification of serum against small antigen targets, the advantages of polyclonal antibodies are further extended.
Figure 1. A) Polyclonal antibodies bind to the same antigen, but different epitopes; and B) monoclonal antibodies bind to the same epitope on a target antigen.